NCT04644315 · OUTCOME

Percentage of Participants With Adverse Events (AEs)

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage
Interval / dispersion: Not reported
Time frame: Approximately 1 year

Groups in this outcome

ALK-positive Solid Tumors

Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
ALK-positive Solid Tumors	1

Reported measurements

Source class 1

Values in Percentage · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
ALK-positive Solid Tumors	100	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
100

denoms

counts
group Id
OG000
value
1
units
Participants

groups

description
Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
id
OG000
title
ALK-positive Solid Tumors

param Type

NUMBER

reporting Status

POSTED

time Frame

Approximately 1 year

title

Percentage of Participants With Adverse Events (AEs)

type

SECONDARY

unit Of Measure

Percentage

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice